Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRIS NASDAQ:DOMH NASDAQ:FBIO NASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$0.59+1.1%$0.76$0.49▼$3.13$23.47M3.08595,035 shs124,985 shsDOMHDominari$3.45+9.4%$3.00$2.68▼$8.40$77.89M0.69132,422 shs181,716 shsFBIOFortress Biotech$2.42+1.5%$2.81$1.60▼$4.53$80.22M1.16827,105 shs141,809 shsSGMOSangamo Therapeutics$0.11-39.7%$0.32$0.11▼$0.77$44.37M1.048.90 million shs36.97 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris0.00%+1.79%+7.66%-32.03%-75.44%DOMHDominari0.00%+3.81%+9.09%-24.24%-47.00%FBIOFortress Biotech0.00%+2.64%-10.38%-24.60%+27.32%SGMOSangamo Therapeutics0.00%-35.71%-55.01%-65.38%-81.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$0.59+1.1%$0.76$0.49▼$3.13$23.47M3.08595,035 shs124,985 shsDOMHDominari$3.45+9.4%$3.00$2.68▼$8.40$77.89M0.69132,422 shs181,716 shsFBIOFortress Biotech$2.42+1.5%$2.81$1.60▼$4.53$80.22M1.16827,105 shs141,809 shsSGMOSangamo Therapeutics$0.11-39.7%$0.32$0.11▼$0.77$44.37M1.048.90 million shs36.97 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris0.00%+1.79%+7.66%-32.03%-75.44%DOMHDominari0.00%+3.81%+9.09%-24.24%-47.00%FBIOFortress Biotech0.00%+2.64%-10.38%-24.60%+27.32%SGMOSangamo Therapeutics0.00%-35.71%-55.01%-65.38%-81.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRISCuris 2.00Hold$17.002,796.08% UpsideDOMHDominari 1.00SellN/AN/AFBIOFortress Biotech 2.00Hold$17.00603.93% UpsideSGMOSangamo Therapeutics 1.75Reduce$5.505,035.39% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, FBIO, DOMH, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026CRISCuris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026SGMOSangamo Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026FBIOFortress Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)3/20/2026CRISCuris HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.003/16/2026FBIOFortress Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/23/2026FBIOFortress Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.002/10/2026SGMOSangamo Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRISCuris$9.44M2.49N/AN/A$0.42 per share1.40DOMHDominari$123.10M0.63N/AN/A$4.28 per share0.80FBIOFortress Biotech$63.26M1.27N/AN/A$2.00 per share1.21SGMOSangamo Therapeutics$39.55M1.12N/AN/A($0.04) per share-2.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRISCuris-$7.58M-$1.19N/A4.52N/A-80.29%N/A-119.73%5/5/2026 (Estimated)DOMHDominari-$22.43M-$3.88N/AN/AN/A-18.22%-176.52%-145.57%5/13/2026 (Estimated)FBIOFortress Biotech$6.82M-$0.13N/A1.60N/A10.77%-41.20%-11.53%5/13/2026 (Estimated)SGMOSangamo Therapeutics-$122.93M-$0.44N/AN/AN/A-310.81%-2,662.06%-132.12%5/11/2026 (Estimated)Latest CRIS, FBIO, DOMH, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/ADOMHDominari-$0.17N/AN/AN/A$30.08 millionN/A5/13/2026Q1 2026FBIOFortress Biotech-$0.22N/AN/AN/A$16.34 millionN/A5/11/2026Q1 2026SGMOSangamo Therapeutics$0.0050N/AN/AN/A$33.73 millionN/A5/5/2026Q1 2026CRISCuris-$0.3267N/AN/AN/A$1.69 millionN/A3/31/2026Q4 2025FBIOFortress Biotech$0.11-$0.21-$0.32-$0.21$26.17 million$16.08 million3/19/2026Q4 2025CRISCuris-$0.4325-$0.50-$0.0675$1.23$3.25 million$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRISCurisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ALatest CRIS, FBIO, DOMH, and SGMO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/4/2026DOMHDominarispecial$0.315/15/20265/15/20265/29/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRISCurisN/A0.490.49DOMHDominariN/A2.492.49FBIOFortress Biotech0.842.492.30SGMOSangamo TherapeuticsN/A0.840.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRISCuris29.97%DOMHDominari42.48%FBIOFortress Biotech96.51%SGMOSangamo Therapeutics56.92%Insider OwnershipCompanyInsider OwnershipCRISCuris5.42%DOMHDominari55.30%FBIOFortress Biotech27.90%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRISCuris6039.98 million37.81 millionNo DataDOMHDominari422.61 million10.11 millionNot OptionableFBIOFortress Biotech17033.22 million23.95 millionOptionableSGMOSangamo Therapeutics480414.28 million397.29 millionOptionableCRIS, FBIO, DOMH, and SGMO HeadlinesRecent News About These CompaniesSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketMay 5 at 9:16 AM | finanznachrichten.deSangamo Therapeutics (SGMO) to Release Earnings on MondayMay 4 at 11:48 AM | marketbeat.comShort Interest in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Expands By 14.0%May 3 at 3:29 AM | americanbankingnews.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest UpdateMay 1, 2026 | marketbeat.comSangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)April 30, 2026 | globenewswire.comSangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB marketApril 29, 2026 | finance.yahoo.comSangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketApril 29, 2026 | globenewswire.comSangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in StockApril 24, 2026 | insidertrades.comGregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) StockApril 23, 2026 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in StockApril 23, 2026 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks ResearchApril 18, 2026 | marketbeat.comHC Wainwright Has Negative Forecast for SGMO FY2026 EarningsApril 7, 2026 | marketbeat.comSangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth UncertaintyApril 1, 2026 | tipranks.comSangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsMarch 31, 2026 | finanznachrichten.deWhy PEPG, SGMO, PHR are among top premarket losers todayMarch 31, 2026 | msn.comSangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ...March 31, 2026 | finance.yahoo.comSangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talksMarch 30, 2026 | seekingalpha.comSangamo: Q4 Earnings SnapshotMarch 30, 2026 | khou.comKSangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comSangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsMarch 30, 2026 | globenewswire.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings CallMarch 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026It's Time to Take Profits on These 2 Overbought Energy StocksBy Dan Schmidt | April 11, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026Shopify’s Valuation Crisis Creates Opportunity in 2026By Thomas Hughes | May 5, 2026CRIS, FBIO, DOMH, and SGMO Company DescriptionsCuris NASDAQ:CRIS$0.59 +0.01 (+1.07%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Dominari NASDAQ:DOMH$3.44 +0.30 (+9.37%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Fortress Biotech NASDAQ:FBIO$2.42 +0.04 (+1.47%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Sangamo Therapeutics NASDAQ:SGMO$0.11 -0.07 (-39.70%) As of 03:10 PM EasternSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas onsemi Stock Dips After Earnings: Why the Dip Is Buyable Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom Atomic Dividends: Big Tech's New Energy Bet Monolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Leading Insider Sales: April Activity Ramps in These Stocks The New Fed Chair Trade: Who Wins When Warsh Takes the Helm? A Prada Payday: Is AMC Back in Style? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
